Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.
Oscar Health's membership jumps 46% to 2.96 million, but seasonal enrollment and medical utilization keep profitability in focus.
OSCR, LQDT and GEO made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 2, 2026.
LCUT, CURI, OSCR, CTOS and CHYM have been added to the Zacks Rank #1 (Strong Buy) List on September 2, 2026.
Oscar Health has surged 109% YTD as membership, revenue and expansion plans strengthen, though its price-to-book multiple tops the industry average.
Oscar Health stock has delivered very strong 3 year gains, yet the broad valuation checks currently lean expensive and do not clearly support it as a bargain. After such a sharp move, investors are trying to work out whether the recent share price now runs ahead of the fundamentals or is still justified by the company’s prospects. Oscar Health has returned about 3.6x over 3 years, which puts extra focus on whether recent gains already reflect much of the potential that investors see in the...
Oscar Health (OSCR) recently reported record first half 2026 results and raised its full year guidance, a combination that appears to have supported renewed investor attention on the stock this month. At a share price of US$30.47, Oscar Health has seen some short term volatility, with a 7 day share price return down 4.9%. However, the 90 day share price return of 37.07% and 3 year total shareholder return of 363.07% suggest momentum has been strong over a longer stretch as investors react to...
Earlier in 2026, Oscar Health reported record first-half financial results and lifted its full-year guidance, prompting analysts to raise their earnings estimates and highlight a low PEG ratio of 0.6 as evidence of relatively modest valuation expectations. This combination of upgraded guidance and analyst estimate revisions underscores how improving profitability expectations are reshaping perceptions of Oscar Health’s earnings power and growth profile. We’ll now examine how Oscar Health’s...
Low P/S and PEG ratios along with a top Zacks Rank. What more could you want?
Urban Outfitters stock tests a buy point while an insurance company bounces off a critical moving average.
SNDR, NESR and OSCR made it to the Zacks Rank #1 (Strong Buy) growth stocks list on August 28th, 2026.
SNDR, NESR and OSCR made it to the Zacks Rank #1 (Strong Buy) growth stocks list on August 26th, 2026.
Oscar Health (OSCR) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
SNDR, NESR and OSCR made it to the Zacks Rank #1 (Strong Buy) growth stocks list on August 24th, 2026.
The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta year in and year out often become the legends of the investing world.
SNDR, NESR and OSCR made it to the Zacks Rank #1 (Strong Buy) growth stocks list on August 20th, 2026.
Oscar Health CEO Mark Bertolini identified uncovered GLP-1 drugs as a potential use case for Hims on the marketplace.
Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits, making them unattractive borrowers.
Oscar Health (OSCR) is back in focus after reporting second quarter 2026 results that swung from a loss to net income of $361.81 million and raising full year earnings guidance. See our latest analysis for Oscar Health. Oscar Health shares have been volatile around the earnings release, with an 11.9% drop reported after the outlook update. The stock still shows a 118.84% year to date share price return and a 109.46% 1 year total shareholder return, suggesting momentum remains strong despite...
Oscar Health stock has delivered a very large 3 year return while the broader valuation checks still lean cautious, with a low value score hinting that the recent re rating may not be a simple bargain story. Oscar Health has returned about 3.6x over the past 3 years, which puts a spotlight on whether recent enthusiasm already prices in much of the progress. Recent profitability and revenue growth can support investor expectations for the business, while concerns around medical cost trends...
Oscar Health’s second quarter saw results well above Wall Street’s expectations, yet the market response was notably negative. Management credited disciplined pricing, technology-driven cost efficiencies, and strong execution in the individual health insurance market for driving year-over-year revenue and margin improvement. CEO Mark Bertolini highlighted that “disciplined pricing, differentiated consumer products and a scalable technology platform” fueled growth, with membership up 46% and admi
Joshua Kushner's Thrive Capital held Amazon shares worth about $215 million as of the end of June, a regulatory filing showed on Friday, adding to the venture capital firm's list of tech and AI investments. Known for its early investments in companies that have gone on to dominate their sectors, including OpenAI, SpaceX and Stripe, the venture capital firm has been looking for opportunities in large technology companies to expand its public-market holdings. • Thrive held 904,038 Amazon shares valued at $215.5 million as of June 30, the filing showed.
Oscar Health, Inc. (NYSE:OSCR) shares closed 11.9% lower at $26.54 on August 6, even after the insurer reported its most profitable first half and raised its full-year outlook. Second-quarter revenue rose 70% year over year to $4.88 billion, while the company swung to net income of $361.8 million from a $228.4 million loss. The stock […]
MTCH, PBI, and OSCR it to the Zacks Rank #1 (Strong Buy) growth stocks list on August 14, 2026.
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the health insurance providers stocks, including Oscar Health (NYSE:OSCR) and its peers.
MTCH, PBI, and OSCR it to the Zacks Rank #1 (Strong Buy) growth stocks list on August 12, 2026.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
